http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009055053-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a6b3b5d7b5da5a01533fffdb25d8aeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b3e9141381fda52836b15207b1ddec5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19ac8f70a9c8f38b6a40465898644986
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e7719145422fd0a1d736d6f533e9cd8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2008-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee92d064070f4ab842ccb225517f76ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc5489b9cf5ab260f5bf2f29d2e07412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eacd54a93a7c83abe812491f9bc71324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8300223eec41dd36fe8957c869f7947e
publicationDate 2009-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2009055053-A3
titleOfInvention Diarylhydantoin compounds as androgen receptor modulators
abstract The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.wherein R3 is selected from the group consisting of hydrogen, cyano, formyl, wherein R1 and R2 together comprise eight or fewer carbon atoms and are, selected from the group consisting of alkyl substituted alkyl and, together with the carbon to with they are linked, a cycloalkyI or substituted cycloalkyl group,
priorityDate 2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006124118-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007127010-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1790640-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9700071-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226574897
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66624946
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226574899
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66624945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226574898
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21566771

Total number of triples: 38.